HeartShare: 心不全のサブタイプと治療目標に対するオミクス、ディープフェノタイピング、電子医療記録の組み合わせ
HeartShareのディープフェノタイピング研究
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Laura Alagna
- 電話番号:312-695-6765
- メール:heartsharestudy@northwestern.edui
研究場所
-
-
California
-
Sacramento、California、アメリカ、95817
- 募集
- University of California Davis
-
コンタクト:
- Maiya Her
- 電話番号:916-734-0230
-
主任研究者:
- Nipavan Chiamvimonvat, MD
-
副調査官:
- Javier Lopez, MD
-
副調査官:
- Martin Cadeiras, MD
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Northwestern University
-
コンタクト:
- Laura Alagna
- 電話番号:312-695-6765
- メール:laura.alagna@northwesterne.du
-
主任研究者:
- Sadiya Khan, MD
-
主任研究者:
- Laura Rasmussen-Torvik, PhD, MPH
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- まだ募集していません
- Mass General Brigham
-
主任研究者:
- Greg Lewis, MD
-
コンタクト:
- Diane Cocca-Spofford
- 電話番号:617-726-8228
- メール:dcoccaspofford@mgh.harvard.edu
-
副調査官:
- Akshay Desai, MD, MPH
-
副調査官:
- Michael Givertz, MD
-
副調査官:
- Scott Solomon, MD
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic
-
主任研究者:
- Barry Borlaug, MD
-
副調査官:
- Margaret Redfield, MD
-
コンタクト:
- Matthew Adolphsen
- 電話番号:507-422-5919
- メール:Adolphsen.Matthew@mayo.edu
-
-
North Carolina
-
Winston-Salem、North Carolina、アメリカ、27157
- まだ募集していません
- Wake Forest University
-
コンタクト:
- Ben Nelson
- 電話番号:336-716-6789
-
主任研究者:
- Dalane Kitzman, MD
-
副調査官:
- Alain Bertoni, MD, MPH
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- University of Pennsylvania
-
コンタクト:
- Tiffany Sharkoski
- 電話番号:215-615-2354
-
主任研究者:
- Julio Chirinos, MD, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adults over 30 years of age.
説明
Inclusion Criteria:
HF Inclusion Criteria (HeartShare Registry)
- Age ≥30 years.
- Prior diagnosis of HF in the EHR (any left ventricular ejection fraction).
Non-HF Group Inclusion Criteria (HeartShare Registry)
- Age ≥30 years.
- No known prior diagnosis of HF or use of loop diuretics.
- No known prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml, if prior laboratory tests are available in the EHR.
HFpEF Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
-
Age ≥30 years.
-
Left ventricular ejection fraction ≥50% measured by echocardiography.
-
Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:
- Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
- Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).
- Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise).
- Elevated H2FPEF score26 (≥5) or HFA-PEFF27 score (≥5).
Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
- Age ≥30 years.
- Left ventricular ejection fraction ≥50% measured by echocardiography.
- No known prior diagnosis of HF or use of diuretics for fluid management.
- No known prior history of BNP ≥75 pg/ml or NTproBNP ≥225 pg/ml, if prior laboratory tests are available in the EHR.
- BNP <75 pg/ml or NTproBNP <225 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center.
Exclusion Criteria:
Exclusion Criteria (HeartShare Registry) The following exclusion criteria apply to both HF and non-HF group participants, unless otherwise indicated.
- For non-HF group: any prior known left ventricular ejection fraction <50%.
- Prior history of solid organ transplantation.
- Prior history of mechanical circulatory support.
- Prior history of non-cardiac cirrhosis.
- Inability to provide written consent to the study.
Exclusion Criteria (HeartShare Deep Phenotyping Cohort) The following exclusion criteria apply to both HFpEF and non-HFpEF group participants, unless otherwise indicated.
-
Life expectancy estimated to be < 1 year.
-
Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension).
-
Any prior known left ventricular ejection fraction <40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation).
-
Clinically significant valvular heart disease defined as:
- Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis.
- Any mitral stenosis.
- Moderate or greater aortic regurgitation.
- Greater than moderate mitral regurgitation.
-
Any planned cardiac surgery or cardiac intervention in the next 3 months.
-
Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator.
-
Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment.
-
Known symptomatic epicardial coronary artery disease that is not revascularized.
-
Any non-elective hospitalization in the preceding 2 weeks.
-
Prior history of solid organ transplantation.
-
Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator.
-
Prior history of mechanical circulatory support.
-
Prior history of non-cardiac cirrhosis.
-
Estimated GFR <20 ml/min/1.73m2 or currently on dialysis.
-
Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator.
-
Inability to provide written consent to the study.
-
Current acute decompensated heart failure.
-
Currently pregnant.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
HFpEF
Participants with HFpEF |
|
Non-HFpEF
Participants without HFpEF |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
駆出率保存型心不全(HFpEF)の参加者数
時間枠:最長5年
|
最長5年
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Sanjiv Shah, MD、Northwestern University
- スタディチェア:Svati Shah, MD, MHS、Duke University
- スタディチェア:Javed Butler, MPH, MBA、Baylor Scott and White Health
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。